secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001493152-24-043187
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera reports Phase 3 sBCC study success; Ameluz-PDT primary endpoint met p<0.0001
--------------------------------------------------------------------------------

- Primary endpoint: 65.5% complete clearance vs 4.8% placebo (p<0.0001); histological clearance 75.9% vs 19.0%.
- Total clearance of all sBCC lesions: 64.1% vs 4.8% (p<0.0001); clinical clearance 83.4% vs 21.4%.
- FDA dossier submission expected around end of Q2/early Q3 2025 after 12-month follow-up ends Dec 2024.
- Study enrolled 187 patients; double-blind, randomized, placebo-controlled, multi-center design.
- BCC is most common skin cancer in US (~3.6M cases/year); sBCC is a subset with limited non-invasive options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315224043187/0001493152-24-043187-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315224043187/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-043187

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer